By demonstrating the shortcomings of an actual model the modeler and readers are defining the value proposition of gathering additional data and further refinementof the model.
An additional refinement is major analyst jockeys on these volatile growthies use a dividend discount model which gives weight to the negative impact of drug patent expirations 5 to 10 years out.